Cargando…
Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation
Although vascular endothelial growth factor inhibition (VEGFi) represents a major therapeutic advance in oncology, it is associated with hypertension and adverse vascular thrombotic events. Our objective was to determine whether VEGFi caused direct vascular dysfunction through increased endothelin-1...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197298/ https://www.ncbi.nlm.nih.gov/pubmed/31449168 http://dx.doi.org/10.1097/HJH.0000000000002230 |
_version_ | 1783528843758272512 |
---|---|
author | Cameron, Alan C. Welsh, Paul Neves, Karla B. Newby, David E. Touyz, Rhian M. Lang, Ninian N. |
author_facet | Cameron, Alan C. Welsh, Paul Neves, Karla B. Newby, David E. Touyz, Rhian M. Lang, Ninian N. |
author_sort | Cameron, Alan C. |
collection | PubMed |
description | Although vascular endothelial growth factor inhibition (VEGFi) represents a major therapeutic advance in oncology, it is associated with hypertension and adverse vascular thrombotic events. Our objective was to determine whether VEGFi caused direct vascular dysfunction through increased endothelin-1 (ET-1) activity or impaired endothelial vasomotor or fibrinolytic function. METHODS: Using forearm venous occlusion plethysmography, we measured forearm blood flow during intra-arterial infusions of bevacizumab (36–144 μg/dl forearm volume per minute) administered for 15–60 min in healthy volunteers (n = 6–8). On two separate occasions in 10 healthy volunteers, we further measured forearm blood flow and tissue plasminogen activator (t-PA) release during intra-arterial bradykinin infusion (100 and 1000 pmol/min) in the presence and absence of bevacizumab (144 μg/dl forearm volume per minute), and the presence and absence of endothelin A receptor antagonism with BQ-123 (10 nmol/min). Plasma t-PA and plasminogen activator inhibitor-1 (PAI-1) concentrations were measured at baseline and with each dose of bradykinin. RESULTS: Baseline blood flow and plasma ET-1, t-PA and PAI-1 concentrations were unaffected by bevacizumab. Bradykinin caused dose-dependent vasodilatation (P < 0.0001) and t-PA release (P < 0.01) but had no effect on plasma PAI-1 concentrations. Neither bevacizumab nor BQ-123 affected bradykinin-induced vasodilatation and t-PA release. CONCLUSION: Acute exposure to bevacizumab does not directly cause endothelial vasomotor or fibrinolytic dysfunction in healthy young volunteers. |
format | Online Article Text |
id | pubmed-7197298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-71972982020-05-21 Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation Cameron, Alan C. Welsh, Paul Neves, Karla B. Newby, David E. Touyz, Rhian M. Lang, Ninian N. J Hypertens ORIGINAL PAPERS: Vascular damage Although vascular endothelial growth factor inhibition (VEGFi) represents a major therapeutic advance in oncology, it is associated with hypertension and adverse vascular thrombotic events. Our objective was to determine whether VEGFi caused direct vascular dysfunction through increased endothelin-1 (ET-1) activity or impaired endothelial vasomotor or fibrinolytic function. METHODS: Using forearm venous occlusion plethysmography, we measured forearm blood flow during intra-arterial infusions of bevacizumab (36–144 μg/dl forearm volume per minute) administered for 15–60 min in healthy volunteers (n = 6–8). On two separate occasions in 10 healthy volunteers, we further measured forearm blood flow and tissue plasminogen activator (t-PA) release during intra-arterial bradykinin infusion (100 and 1000 pmol/min) in the presence and absence of bevacizumab (144 μg/dl forearm volume per minute), and the presence and absence of endothelin A receptor antagonism with BQ-123 (10 nmol/min). Plasma t-PA and plasminogen activator inhibitor-1 (PAI-1) concentrations were measured at baseline and with each dose of bradykinin. RESULTS: Baseline blood flow and plasma ET-1, t-PA and PAI-1 concentrations were unaffected by bevacizumab. Bradykinin caused dose-dependent vasodilatation (P < 0.0001) and t-PA release (P < 0.01) but had no effect on plasma PAI-1 concentrations. Neither bevacizumab nor BQ-123 affected bradykinin-induced vasodilatation and t-PA release. CONCLUSION: Acute exposure to bevacizumab does not directly cause endothelial vasomotor or fibrinolytic dysfunction in healthy young volunteers. Lippincott Williams & Wilkins 2020-02 2019-08-19 /pmc/articles/PMC7197298/ /pubmed/31449168 http://dx.doi.org/10.1097/HJH.0000000000002230 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | ORIGINAL PAPERS: Vascular damage Cameron, Alan C. Welsh, Paul Neves, Karla B. Newby, David E. Touyz, Rhian M. Lang, Ninian N. Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation |
title | Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation |
title_full | Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation |
title_fullStr | Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation |
title_full_unstemmed | Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation |
title_short | Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation |
title_sort | acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation |
topic | ORIGINAL PAPERS: Vascular damage |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197298/ https://www.ncbi.nlm.nih.gov/pubmed/31449168 http://dx.doi.org/10.1097/HJH.0000000000002230 |
work_keys_str_mv | AT cameronalanc acutevasculareffectsofvascularendothelialgrowthfactorinhibitionintheforearmarterialcirculation AT welshpaul acutevasculareffectsofvascularendothelialgrowthfactorinhibitionintheforearmarterialcirculation AT neveskarlab acutevasculareffectsofvascularendothelialgrowthfactorinhibitionintheforearmarterialcirculation AT newbydavide acutevasculareffectsofvascularendothelialgrowthfactorinhibitionintheforearmarterialcirculation AT touyzrhianm acutevasculareffectsofvascularendothelialgrowthfactorinhibitionintheforearmarterialcirculation AT langniniann acutevasculareffectsofvascularendothelialgrowthfactorinhibitionintheforearmarterialcirculation |